(NASDAQ: LPCN) Lipocine's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.
Lipocine's earnings in 2025 is -$5,475,238.On average, 4 Wall Street analysts forecast LPCN's earnings for 2025 to be -$11,127,735, with the lowest LPCN earnings forecast at -$10,718,558, and the highest LPCN earnings forecast at -$11,425,874. On average, 4 Wall Street analysts forecast LPCN's earnings for 2026 to be -$10,249,975, with the lowest LPCN earnings forecast at -$12,350,826, and the highest LPCN earnings forecast at -$7,869,862.
In 2027, LPCN is forecast to generate -$5,946,118 in earnings, with the lowest earnings forecast at -$5,712,937 and the highest earnings forecast at -$6,121,004.